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Increased bone mineral density (BMD), as a marker of higher integrated estrogen exposure over
time, could be an important risk factor for postmenopausal breast cancer. In the Study of
Osteoporotic Fractures 8065 non-black women age 65 years and older were followed for an
average of 3.2 years. There were 121 incident breast cancer cases. The age adjusted incidence
rate/i 000 person years of breast cancer was substantially higher among women with high BMD
at several measured bone sites. There was approximately a 2-fold higher risk of breast cancer for
women in the upper as compared to the lower 25th percentile of BMD. Considerable controversy
exists about the association of hormone replacement therapy (HRT) and increased risk of breast
cancer. In this paper we modeled the effects of selection for HRT, presuming that women with
lower BMD would be more likely to be on HRT, then estimated the observed versus potential risk
of breast cancer among HRT users as compared to nonusers. The model suggests that the
potential risk of breast cancer associated with HRT could be greatly underestimated and that
postmenopausal women with high BMD who are placed on HRT could have a substantially
increased risk of breast cancer. This model of increased risk of breast cancer associated with
BMD and HRT needs to be evaluated within clinical trials and larger observational studies that
include measures of BMD. Environ Health Perspect 105(Suppl 3):593-599 (1997)
Key words: bone mineral density, estrogen, hormone replacement therapy, breast cancer
Introduction
The use of exogenous estrogen and
progesterone therapy among postmeno-
pausal women and the subsequent risk of
breast cancer remains a very controversial
subject. There is little consistency in rela-
tive risks (RR) of hormone replacement
therapy (HRT) and breast cancer across
many studies (1). The widespread and
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increasing use of HRT could be of major
concern if such therapy was actually asso-
ciated with an increased risk of breast
cancer. There are several factors that could
account for inconsistent study results on
the relationship between exogenous hor-
mone therapy and risk of breast cancer.
The first and most important is probably
selection bias among postmenopausal
women given HRT. Women at lower risk
for breast cancer are more likely to be
placed on HRT (2).
Second, the duration of follow-up for
women on HRT has not been long enough
to identify either a morbidity (i.e., an
increase in incidence) or increased mortality
from breast cancer (3). A third hypothesis
is that estrogen or estrogen/progesterone
therapy is not an important determinant of
the risk ofbreast cancer (4).
In this paper we will briefly review the
model for the development ofbreast cancer
among postmenopausal women. Using
data from the Study of Osteoporotic
Fracture (SOF) we measured the relation-
ship between bone mineral density (BMD)
and risk ofbreast cancer. We then modeled
the potential risk of breast cancer for
women on HRT based on BMD as a selec-
tion criteria. We also investigated whether
changes in the selection criteria for HRT
use (that is, placing women who have high
BMD, high body weight, or high lipid lev-
els on HRT) could increase the estimated
risk for breast cancer.
A plausible hypothesis linking host
susceptibility, environmental agents, and
hormones to the risk ofbreast cancer is as
follows: a) The early neoplastic changes of
breast cancer are caused by exposure to a
variety of chemical carcinogens that are
secreted by breast glandular tissue. The
exposure is more important at an earlier
age (5,6). Susceptibility ofbreast tissue to
specific agents is clearly age dependent, as
suggested by the substantially reduced risk
of breast cancer at first full-term preg-
nancy. This is probably due to differentia-
tion of breast glandular tissue, and
differences in the risks of breast cancer
related to age with exposure to radiation (a
causal agent for breast cancer) (7). b) The
growth ofbreast neoplasms to clinical dis-
ease is primarily determined by sex steroid
hormone levels, especially estrogens, and
estogen metabolism (5,8,9). c) The pro-
gression to metastatic disease may be
related to a secondary exposure to carcino-
gens in cells with higher mitotic activity
secondary to hormone stimulation later in
life (5). d) Genetic host susceptibilityplays
an important role, possibly related to the
metabolism of the carcinogens, such as
P450 polymorphisms (10,11), genetic
polymorphisms that affect sex steroid hor-
mone metabolism or receptors (12), or
mutations in oncogenes or suppressor
genes such as p53-as yet unknown effects
related to BRCA (13).
Endogenous Estrogen
andBreastCancer
The levels ofendogenous estrogen exposure
at the breast and the specific metabolites of
estrogen (14) play key roles in determining
whether early neoplastic changes in the
breast progress to clinical breast cancer and
metastatic disease. Breast cancer may be
prevented by modulating the levels and
metabolism ofestrogens, either by drugs or
by lifestyle modification. Similar increased
estrogen exposure at the breast, either due
to lifestyle risk factors, genetic factors, or
exogenous hormone therapy, i.e., HRT
could result in an increased incidence of
breast cancer (14).
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The level ofestrogens and progesterone
are much higher among pre- as compared
to postmenopausal women (15,16). The
variability of blood estrogen levels during
the menstrual cycle has made it extremely
difficult to evaluate the relationship between
premenopausal blood estrogen levels and
the risk of breast cancer (16,17). It is
unclear whether peak estogen levels during
the menstrual cycle, average estrogen levels
over the cycle, or perhaps, levels during the
luteal or follicular phases are important risk
factors for breast cancer.
The importance ofendogenous estrogen
levels and risk of premenopausal breast
cancer are primarily documented by the
substantial reduction in risk associated with
oophorectomy (18) (especially at an early
age), and the benefits of oophorectomy
(19) and tamoxifen (20) in improving sur-
vival among premenopausal breast cancer
patients. Genetic factors (i.e., host suscep-
tibility) play a very important role in pre-
menopausal breast cancer. The levels of
endogenous estrogens necessary to stimu-
late growth of breast cancer cells may be
lower than found in most women during a
normal menstrual cycle. An effect of
BRCA protein may be to reduce the risk of
breast neoplasia by decreasing the active
mitotic activity due to increased exposure
to estrogens or estrogen/progesterone
during menstrual cycles.
Postmenopausal estrogens are much
lower than premenopausal levels and are
primarily produced by the aromatization of
androstenedione in fat tissue (21). The pri-
mary estrogen in postmenopausal women is
estrone, which is not bound to sex hor-
mone-binding globulin. A small amount of
testosterone is also produced for a period of
time by the postmenopausal ovary (22).
The level ofpostmenopausal estrogens may,
therefore, be related to the production of
androstenedione in the adrenal gland and
the aromatization of androstenedione to
estrone, primarily in fat tissue.
Studies of the relationship between
blood estradiol and estrone levels among
postmenopausal women and the risk of
breast cancer have had major limitations.
The blood levels ofpostmenopausal estro-
gens are very low. Without careful atten-
tion to measurement techniques, cross
reactivity, lack ofaccuracy, and variability
ofthe assay may result in reported spurious
levels ofestradiol (23).
The levels ofestrone and estradiol early
in the postmenopause (first several years
after the menopause) are related to residual
ovarian secretion of estrogens, as well as
the aromatization of androstenedione
(15,16,24). Estradiol levels early in the
postmenopause correlate poorly with levels
later in menopause and there is no apparent
relationship between estrogen levels in pre-
menopause and levels in the same women
in postmenopause (24). Postmenopausal
estradiol levels are not related to pre-
menopausal level nor to the levels early in
the postmenopause.
Estradiol is weakly bound to sex
hormone-binding globulin and recent
interest has focused on whether the free
estradiol levels may be a better measure of
risk ofbreast cancer. Free levels ofestradiol
are extremely difficult to measure accu-
rately among postmenopausal women.
Levels of sex hormone-binding globulin
may be used to estimate the percentage of
free estradiol (25).
Endogenous Estrogensand
OtherBiologicalAssociations
The measurement of postmenopausal
estrogen levels do appear to have other bio-
logical associations in addition to possible
risk of postmenopausal breast cancer.
Women who report hot flashes during the
perimenopause and early in the post-
menopause have lower blood estradiol levels
(26). A positive association has been noted
between blood estradiol and estrone levels
and BMD among postmenopausal women
that appears to be independent ofobesity
(27). There is a suggestive association of
higher estradiol and lower low-density
lipoprotein cholesterol (LDLc) levels among
postmenopausal women (28).
There have been both case-control and
longitudinal studies of the association of
endogenous estrogen levels and risk of
breast cancer (1,4,5). The results of these
studies are inconsistent. More recent
prospective studies have documented an
increased risk ofbreast cancer with higher
levels ofpostmenopausal blood estrogens,
especially free or non-sex hormone-bound
estradiol levels (29).
However, all ofthe associations between
blood estrone and estradiol levels and
biological measurements (breast, bone,
hypertrophy, lipids) are relativelyweak, due
to the variability of the measurements of
estrone and estradiol. The blood levels are a
measure of production, secretion, and
metabolism ofestrogens (16). Estrogen lev-
els at specific tissue such as the breast may
not necessarily be measured by blood levels
(30). Fat tissue in the breast can aromatize
androstenedione to estrone and then to
estradiol. Sulfatases, also in the breast, can
convert estrone sulfate to estrone. Therefore,
exposure of the postmenopausal breast to
estrogens is certainly higher and may be
quite different from levels reported in the
blood (5,31). It is extremely difficult to
measure estrogen levels in breast tissue in
epidemiological studies among postmeno-
pausal women, especially in prospective
studies where large numbers of healthy
women must be followed over a long period
oftime.
Determinants of
Endogenous Estrogens
The primary determinants ofpostmeno-
pausal estrone andestradiol levels are obesity
or body fat. In the Healthy Women Study
we showed that postmenopausal levels (5-8
years postmenopausal) ofboth estrone and
estradiol were directly related to body mass
index (BMI) (28). The strong association
between BMI and postmenopausal estrone
and estradiol levels has been documented in
many epidemiological studies (5). Several
studies show an association between obesity
among postmenopausal women and risk of
breast cancer (5).
Obesity and body fat distribution are
major determinants ofsex hormone-bind-
ing globulin. The sex hormone-binding
globulin levels decrease substantially with
increasing levels of obesity among post-
menopausal women (32). The degree of
obesity (33), the amount of intraabdomi-
nal fat, and the waist-to-hip ratio (34)
have all been related to the increased risk
of breast cancer. The levels of sex hor-
mone-binding globulin and any relation-
ship to breast cancer may, therefore, be
only a measure ofthe degree ofobesity and
the high correlation with levels of sex
hormone-binding globulin.
Estradiol is also more weakly bound
to sex hormone-binding globulin than
testosterone (32). The levels of sex hor-
mone-binding globulin may be a measure
ofthe relative amount offree testosterone
to free estradiol. This ratio (estradiol/
testosterone) could be related to risk of
breast cancer. Recent studies have shown
that higher free testosterone levels in post-
menopausal women are risk factors for
breast cancer (35).
BoneMineral Densityand
Endogenous Estrogens
BMD could be a significant pre- and
postmenopausal marker for long-term
estrogen exposure. Therefore, measure-
ment of BMD, even in older women,
could be a significant measure oflifetime
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estrogen exposure. Clearly, diet, genetic
attributes, and other growth factors affect
BMD. Estrogens, however, play a crucial
role in BMD in women. Ifhigher lifetime
exposure to endogenous estrogens is associ-
ated with higher BMD, then we hypothe-
size that women with higher BMD should
have an increased riskofbreast cancer (36).
Bone contains estrogen receptors and is
highly sensitive to estrogen levels (37).
Early age at menarche, length ofreproduc-
tive life, and normal cycling are associated
with higher BMD (38).
The peri- to postmenopause is asso-
ciated with substantial bone loss due to the
decrease in estrogen production by the
ovary (39). As noted, we have found that
endogenous estrogen levels are indepen-
dently related to BMD among older
women (27). Estrogen drug therapy and
resulting higher blood estrogen levels are
also associated with a decrease in the rate of
bone loss and fractures among older
women (40). Greater degrees of obesity
and higher estrogen levels correlate with
higher BMD, even for nonweight-bearing
sites (27).
Methods
The SOF recruited 9704 women aged 65
years and older in four locations in the
United States: Baltimore, Maryland;
Minneapolis, Minnesota; Monongahela
Valley, Pennsylvania; and Portland,
Oregon (41,42). All women studied were
white. Approximately 1 year after their
baseline examination, participants com-
pleted a questionnaire that included per-
sonal history of breast cancer. Further
follow-up to determine incidence ofbreast
cancer was completed approximately 3.2
years after this questionnaire (1.0-6.6 years
on average).
Breast cancer analysis was limited to
women who provided information regard-
ing their breast cancer status both at the
year 1 exam and approximately 3.2 years
later. Women who reported breast cancer
at year 1 were considered to be prevalent
cases and excluded from the analysis
(n= 506). Three hundred sixty-five women
died before complete follow-up informa-
tion on breast cancer was available. For 30
ofthewomen, breast cancer was the under-
lying cause ofdeath. Of those 30 deaths,
22 were prevalent cases (women had
reported a history ofbreast cancer at the
year 1 exam). Three were considered possi-
ble incident cases; five were missing infor-
mation about breast cancer history. The
study included 121 breast cancer cases.
Medical records for all breast cancer cases
were reviewed to validate the diagnosis.
Four of the 121 breast cancer cases were
considered carcinoma in situ (41).
BMD was measured at entry to the
study using an Osteo analyzer (Siemens
Osteon, Wahiwa, HI). The distal and
midradius and the calcaneus were scanned
at the baseline examination. During a sec-
ond clinical examination (approximately 2
years after baseline), measurements of
BMD at the proximal femur and lumbar
spine (L1-4) using Dual Energy X-ray
Absorptiometry (DEXA) 1000 (Hologic,
Waltham, MA) were added (42). Both
measurements are associated with relatively
small coefficients ofvariation ofthe mea-
surements (1.5% distal radius, 2.0% mid-
radius, 1.3% calcaneous, 1.2% femoral
neck and 1.5% lumbar spine) (42).
The study included information about
weight, height, self-reported height at age
25 years, reproductive history, family
history of breast cancer, and history of
benign breast disease. Blood samples were
also obtained and are currently being
analyzed forsex-steroid hormone levels (41).
Results
The age-specific incidence rates (95% CI)
of breast cancer (per 1000 person years)
were (n= 56) 4.59 (3.53-5.97) age 65 to
69 years; (n=41) 4.85 (3.57-6.60) age 70
to 74 years; (n=25) 3.94 (2.66-5.83) age
75 years and older. The incidence rates are
comparable to those reported for the SEER
study (43).
The incidence ofbreast cancer increased
with the level of BMD at all measured
anatomical sites. For example, at the proxi-
mal radius the incidence (95% CI) was 2.5
(1.46-4.35) in the lowest quartile ofBMD
and 4.06 (2.06-6.23) in the second quar-
tile, 5.10 (3.50-7.43) in the third quartile,
and 5.48 (3.86-7.79) in the fourth quartile
per 1000 person years. Adjustment for age
and other breast cancer risk factors did not
affect the association of BMD with risk of
breast cancer. Current estrogen therapy use
was reported in a greater proportion of
breast cancer cases (20%) than controls
(14%) (p=0.10). The RR associated with
current estrogen use (1.45) is consistent
with several other studies of long-term
estrogen use. Current estrogen users had
higher BMD than nonusers. Restriction of
the analysis, however, to women who were
not current estrogen users had no effect on
the association between BMD and risk of
breast cancer. Thus, women with high
BMD (upper quartile) at any one of five
sites had approximately 2.5- to 3-fold
greater risk ofincident breast cancer.
The measurements of BMD at the
three sites (distal and proximal radius and
calcaneus) are not perfectly correlated.
Therefore, we further tested the hypothesis
to determine if women who have low
BMD at all three sites (proximal and distal
radius and the oscalsis) (i.e., presumably
women with the lowest long-term estrogen
exposure) would be at very low risk of
breast cancer. At all three sites, 793 con-
trols and only three cases were in the
lowest quartile ofBMD. The RR ofbreast
cancer was greatly reduced for women with
low BMD at all three sites [0.23 (0.07-.72)
(Figure 1)] compared with women who
were in the top quartile of BMD for at
least one site, although the number ofcases
was relatively small and confidence intervals
fairlywide.
Preliminary results from the SOF
recently reported by Cummings et al. (44),
further support the association oflow risk
ofbreast cancer with possible osteoporosis
or low BMD. Vertebral fractures were
ascertained in the SOF at baseline byX-ray
and morphometric analysis. Women with
vertebral fractures at baseline had 62%
lower risk ofsubsequent breast cancer over
the 3.2 years of follow-up [RR 0.4
(0.2-0.08)] than women without vertebral
fractures. Even adjustment for BMD had
little effect on the strong reduction in risk
ofbreast cancer associated with vertebral
fracture, as diagnosed byX-ray.
Model: BoneMineralDensity,
Exogenous Estrogen, and
BreastCancer
We modeled the results ofthe SOF (the
study of the relationship between BMD
and risk ofbreast cancer) in order to further
7-
6 2
5
2-
0
3Sites ISite 2Sites 3Sites
bottom quartile topquartile topquartile topquartile
Figure 1. Relative risk of breast cancer by bone min-
eral density. Women with top quartile BMD at one,
two, or three sites compared to women with lowest
BMD atthree sites.
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test the hypothesis that: a) women with
low BMD are estrogen deficient and more
likely to have been placed on HRT in the
past, resulting in a substantial selection bias
for HRT and risk ofbreast cancer (i.e. low
risk women with low BMD were placed on
HRT), and b) the reported weak or lack of
association between HRT and breast
cancer would be due to the selection of
women with low BMD and lower risk of
breast cancer.
We created an artificial sample of
40,000 women, assuming that 30% would
be hormone (estrogen or estrogen/proges-
terone) users, and that among the hormone
users, 50% would be in the lowest quartile
of BMD, 25% in quartile two, 15% in
quartile three, and 10% in quartile four
(Table 1). We believe that this was reason-
able, as women with artificial menopause,
symptomatology, or risk of osteoporosis
were more likely to have been placed on
HRT in the past.
We used the incidence rates from the
SOF (41), approximately 4.5/1000/year.
We estimated that over 4 years there would
be approximately 72 cases of incident
breast cancer. The rates would vary from
2.5/1000 in the lowest quartile ofBMD to
5.5/1000/year in the highest quartile
(Table 1). We then presumed that the risk
of breast cancer was increased 3-fold
among hormone users. An estimated
2.3-fold risk would be observed without
knowledge ofselection for BMD compar-
ing HRT users and nonusers. A true 2-fold
increased risk, again without knowledge of
selection for BMD, would appear to be a
1.3-fold increased risk, and true 1.5-fold
increased risk due to HRTwould appear to
be a 1.1-fold increase in the risk ofbreast
cancer. It is possible, therefore, that the rela-
tively low risk ofbreast cancer among HRT
users reported in some past studies, was due
to selection for women who had lower
endogenous estrogen levels, i.e., lower
BMD, initiallyatlowerriskofbreast cancer.
We next selected HRT so that its major
indications were the primary prevention of
cardiovascular disease (i.e., high LDLc, low
high-density lipoprotein cholesterol
[HDLc], obesity) and osteoporosis. Women
were placed on HRT without knowledge
oftheir BMD. It is much more likely now
that women with higher BMD and, per-
haps, greater risk ofbreast cancer would be
placed on HRT. We therefore modeled the
use ofHRT presuming there was no selec-
tion for BMD and evaluated the potential
risk ofbreast cancer associated with BMD
and HRT.
Women with high BMD (top quartile)
would have an estimated 3.3-fold increased
risk ofbreast cancerwith a 1.5-fold increase
due to HRT, as compared to women with
low BMD not on HRT (Table 2). Over a
20-year period, between the ages of 52 to
72 years, these women would have an esti-
mated 17% risk of breast cancer (one in
six). This is substantially higher than their
risk ofmyocardial infarction. For example,
in the Framingham Study follow-up, the
cumulative incidence of coronary heart
disease (excluding angina pectoris), in
Table 1. Observed annual risk of breast cancer by quartile of bone density and use of HRT among a cohort of
40,000 women. Assumes a 3-fold increased risk of breast cancer among HRT users, and that women with low
bone density are more likely to use HRT.
Not on HRT On HRT
Incidence/ Breast cancer, 3-fold increased risk,
1000 quartile n no. cases RR n HRT, % no. cases
2.5 4,000 10 3 6,000 50 45
11 4.0 7,000 28 3 3,000 25 36
III 5.0 8,200 41 3 1,800 15 27
IV 5.5 8,800 48 3 1,200 10 19
Total 28,000 127 12,000 100 127
Rate 4.5 2.3 10.6
Table 2. Estimated relative risk of breast cancer for women in the highest quartile of BMD assuming a 2.2-fold
increased risk of breast cancer between highest and lowest quartile of BMD, and varying risk due to HRT (inci-
dence quartile 1=2.5/1000, quartile 4=5.5/1000/year).
Breast cancer risk Estimated incidence, Riskcompared to quartile 1 Cumulative incidence
due to HRT quartile 4 No HRT, 2.5/1000 20-year breast cancer, %
3 16.5 6.6 33.0
2 11.0 4.4 22.0
1.5 8.3 3.3 16.6
1.0 5.5 2.2 11.0
women age 50 to 70 was about 11%, simi-
lar to the incidence of breast cancer for
women in quartile four of BMD, even
withoutadded HRT.
The model presumes a relatively simple
additive effect ofBMD and use ofHRT. It
is possible that the use of HRT only
increases the risk of breast cancer among
women with low BMD and estrogen
deficiency relative to that of all other
women, and would have little effect on
women who already had high BMD. Ifthis
model were true, women with low BMD,
even with a 3-fold increased risk ofbreast
cancer, would not be identified in current
epidemiological studies; the overall risk
associated with HRT compared with non-
HRT for the entire population would only
be a 1.4-fold increased risk, similar to that
found in many of the current studies,
unless measures ofBMD were available.
The increased risk of breast cancer
may be greater in women with high BMD
and more than additive. If such a situa-
tion exists, it is possible that there may be
a group ofwomen at extremely high risk
of breast cancer who might inadvertently
be placed on HRT for cardiovascular
protection and be at extremely high risk
ofbreast cancer.
Discussion
Why exogenous estrogens or estrogen/
progesterone, i.e., in HRT, are not associ-
ated with a substantial increased risk of
breast cancer among postmenopausal
women, given that endogenous estrogens
are an important determinant of breast
cancer, is a major unanswered question.
Possible explanations for the failure to doc-
ument an increased risk ofbreast cancer
among HRT users has focused on several
areas: a) The duration offollow-up from
time ofinitial HRT use and its association
in several studies with an increased risk of
breast cancer. The discovery in 1975 ofthe
association between estrogen therapy and
uterine cancer resulted in substantial reduc-
tion in the use of estrogen, especially
among women with intact uteruses. It was
not until approximately 1987 (45) that
HRT began to substantially increase again,
primarily because of the availability of
estrogen/progesterone combinations that
reduced the risk of uterine cancer, and
growing evidence for the possible benefits
ofestrogen replacement therapy in reducing
the risks ofosteoporotic fracture and coro-
nary heart disease. Thus, the majority of
current hormone users have been on HRT
for a relatively short length oftime (perhaps
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from the late 1980s to the 1990s), or are
women who had an artificial menopause or
hysterectomy and therefore did not have
the risk ofuterine cancer. Another major
problem is selection for longer term use.
Many older women do not continue hor-
mone therapy (46). In the Perimenopausal
Estrogen/Progesterone Intervention (PEPI)
trial, 37% of the women with intact
uteruses on conjugated estrogens alone dis-
continued therapy by 36 months (47).
This was explained by the high rates ofade-
nomatous or atypical endometrial hyperpla-
sia in women assigned to unopposed
estrogens. The incidence ofwomen who
were unable to continue unopposed estro-
gens for any reason was 20% within 1 year,
45% at 2 years, and 55% at 3 years. It is
possible, based on these results from PEPI,
that women with intact uteruses who have
been on long-term estrogen therapy in the
past have metabolized the drug differently.
Women with a lower estrogen exposure at
the uterus and perhaps also at the breast
would have a differential tissue response to
estrogens including absence ofhyperplasia,
bleeding, andperhaps breast neoplasia.
Other studies have also shown a fairly
high frequency ofbleeding associated with
both estrogens alone, aswell as estrogens and
progesterone, among postmenopausal hor-
mone users (48), and dearly there is aselec-
tion for women who will stay on long-term
therapy. b) HRT depresses serum levels of
insulin-like growth factor I (IGF-1), while
endogenous estrogens stimulate IGF-1
levels. Premenopausal women have higher
IGF-1 levels than postmenopausal women.
IGF-1 or IGF-2 and their binding proteins
may be important for growth of breast
cancer cells (49). However, the autocrine/
paracrine levels ofIGF-1 or -2 at the breast,
may have little relationship to blood levels
(50). c)The most likely hypothesis to
explain why HRT is not associated with a
greater risk ofbreast cancer is related to
selection for HRT use, including prior
artificial menopause or hysterectomy, low
body weight, and greater prevalence of
menopausal symptomatology, all ofwhich
areassociatedwithlowbloodestrogen levels.
Several studies have attempted to adjust
for potential selection bias, HRT use, and
risk ofbreast cancer. The adjustment fac-
tors may have little association with risk of
postmenopausal breast cancer, especially
among older women. The adjustment vari-
ables may not be good measures ofprior
endogenous estrogen exposure, especially
with the biological dose at the breast and
other tissues.
In recent years, the current use ofHRT
for the prevention ofcardiovascular disease
and osteoporosis, as well as a shorter term
use for the treatment ofmenopausal symp-
tomatology and estrogen deficiency has
greatly increased the population ofwomen
on HRT. Women now remain on HRT
for longer periods oftime and start ther-
apy soon after the menopause, in order to
reduce the risks of both coronary heart
disease and osteoporosis.
The combination oflong-term use and
therapy initiation fairly early after the
menopause will ultimately result in many
more long-term estrogen or estrogen/
progesterone users. Furthermore, whereas
women were selected for HRT in the past
based on relative estrogen deficiency, many
ofthe current potential long-term users are
being placed on therapy for prophylaxis,
especially for coronary heart disease and
osteoporosis. This presents an interesting
problem, because obese women are more
likely to have lower HDLc and higher
LDLc after the menopause and, therefore,
would be considered to be candidates for
hormone replacement therapy (51). How-
ever, such women probably have higher
estrogen levels, especially ifthey gained
weight from the pre- to the postmenopause,
resulting in an increase in their LDLc,
decrease in their HDLc, and possibly an
increase in their risk ofbreast cancer. It is
possible that women at greater risk ofbreast
cancer because oflong-term higher levels of
endogenous estrogens, are now being
exposed to further high levels ofestrogens
with estrogen/progesterone therapy.
The increased risk ofbreast cancer in
older women associated with higher BMD
and presumably increased endogenous
estrogen exposure may not result in
metastatic disease or substantial morbidity
or mortality. It is possible that without
further exposure to other carcinogens or a
genetic susceptibility to metastatic disease,
the breast cancers identified primarily by
mammography among older women are of
little clinical importance.
There could be an important inter-
action between stimulants ofbreast glan-
dular epithelial cells by estrogen and
exposure to carcinogens. The progression
to metastatic disease may be linked to
either further exposure to carcinogens or
genetic host susceptibility, including
metabolism of estrogen such as through
2- and 16a-hydroxylation ofestrone (9).
Current clinical trials, including the
Women's Health Initiative (i.e., very low
fat/high fiber intake) (52), the tamoxifen
trial (the primary prevention of breast
cancer in high risk women) (53) and trials
ofluteinizing hormone-releasing hormone
antagonists amongwomen atveryhigh risk
ofpremenopausal breast cancer (54), have
the potential for substantially modifying
the risk, primary prevention, and decreased
incidence ofbreast cancer. The difficulties
in maintaining long-term weight reduc-
tion, especially among postmenopausal
women, have precluded very important
trials ofthe effects ofweight loss among
postmenopausal women and the risks of
breast cancer.
Potential risks are associated with the
reduction ofendogenous estrogen levels
across the population, since BMD is
directly related to endogenous estrogen lev-
els. Reduction ofestrogen levels may result
in decreased BMD and an increase in risk
of osteoporotic fractures. Similarly, high
endogenous estrogen levels among post-
menopausal women may provide protec-
tion against cardiovascular disease and
reduction ofthese levels could be associated
with an increase in coronaryheart disease.
It has taken at least 15 years to recognize
the association between estrogen therapy
and uterine cancer. The use of HRT con-
tinues to increase in the United States. The
indications for therapy are changing
towards a view ofmenopause as a disease,
and the indication for hormone therapy
towards a modifier ofthe potential risk of
cardiovascular disease and osteoporosis.
In the future, the incidence ofmorbidity
and mortality due to breast cancer for
women on estrogen or estrogen/proges-
terone therapy for longer periods of time
may increase. The absence ofgood clinical
trials, to evaluate both the benefits in terms
ofosteoporosis and cardiovascular disease,
and the risks ofbreast cancer amongwomen
on HRT, is extremely unfortunate.
The most likely scenario is that HRT is
ofbenefit for some women at high risk for
osteoporosis and coronary heart disease,
and not beneficial forwomen at higher risk
for breast cancer. The availability ofalter-
native therapies for both coronary heart
disease and osteoporosis further increases
the need to determine, in clinical trials, the
risks and benefits ofhormone replacement
therapy. It is now feasible to quantify a
woman's risk of cardiovascular disease,
osteoporosis, and likely breast cancer.
Therapies can be tailored for the individual
needs ofa woman based on risk evaluation
rather than the dassification ofmenopause
as a disease requiring universal hormone
replacement therapy.
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